About this trial
Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events \[1,2\]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength \[2-4\]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement \[5\]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes \[6,7\]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years
Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
American Society of Anesthesiologists (ASA) physical status I-III
Disqualifiers
Daily opioid use or chronic pain syndrome
Diabetic or other clinically diagnosed peripheral neuropathy
Coagulopathy
Infection at the injection site
Trial population
Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
Trial design
Cohort
Prospective
Treatments tested in this trial
Adductor Canal Block (ACB) Only
Procedure/SurgeryThe adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia.
Treatment groups
Trial outcomes
Primary outcomes
ACB Failure
ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.
Secondary outcomes
Secondary outcome
1\. Numeric Rating Scale (NRS) Pain Scores NRS pain scores at rest and during a standardized movement (active 90° knee flexion) will be recorded at postoperative 1, 6, 12, and 24 hours.
Tramadol Consumption
2\. Total Tramadol Consumption Total tramadol consumption (mg) during the first 24 hours following ACB administration will be recorded.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.